SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 10, 2003
|
AVANT IMMUNOTHERAPEUTICS, INC. |
||||
|
(Exact name of registrant as specified in charter) |
||||
|
|
|
|
|
|
|
Delaware |
|
0-15006 |
|
13-3191702 |
|
(State
or other jurisdiction |
|
(Commission file number) |
|
(IRS
employer |
|
|
|
|
|
|
|
119 Fourth Avenue |
||||
|
(Address of principal executive offices) (Zip code) |
||||
|
|
|
|
|
|
|
Registrant’s telephone number, including area code: |
||||
|
(781) 433-0771 |
||||
ITEM 5. OTHER EVENTS.
On March 10, 2003, AVANT Immunotherapeutics, Inc. announced that it had enhanced its intellectual property portfolio through the acquisition of certain intellectual property from Pharmacia Corporation, including a portfolio of pending patent applications. These patent applications are directed to products or methods for stimulating an immune response against cholesteryl ester transfer protein (CETP), which mediates an important cholesterol transport mechanism.
The press release issued by AVANT Immunotherapeutics, Inc. (which is attached hereto as Exhibit 99.1) is incorporated herein by reference.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
|
(a) |
|
Financial Statements of Business Acquired: |
|
Not Applicable |
|
|
|
|
|
|
|
|
|
(b) |
|
Pro Forma Financial Information: |
|
Not Applicable |
|
|
|
|
|
|
|
|
|
(c) |
|
Exhibits: |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.1 |
Press Release of AVANT Immunotherapeutics, Inc. dated March 10, 2003 |
||
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
AVANT IMMUNOTHERAPEUTICS, INC. |
||
|
|
|
|
|
|
|
|
|
|
|
Date: March 12, 2003 |
By: |
/s/ Avery W. Catlin |
|
|
|
|
Avery W. Catlin |
|
|
|
|
Senior Vice President and |
|
3
EXHIBIT INDEX
|
Exhibit No. |
|
Description |
|
|
|
|
99.1 |
|
Press Release of AVANT
Immunotherapeutics, Inc. dated |
4